Reneo Pharmaceuticals (RPHM)
(Delayed Data from NSDQ)
$1.35 USD
0.00 (0.00%)
Updated Aug 9, 2024 03:59 PM ET
After-Market: $1.35 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum D VGM
Reneo Pharmaceuticals, Inc. (RPHM) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$1.90 | $3.00 | $1.20 | 40.74% |
Price Target
Based on short-term price targets offered by three analysts, the average price target for Reneo Pharmaceuticals, Inc. comes to $1.90. The forecasts range from a low of $1.20 to a high of $3.00. The average price target represents an increase of 40.74% from the last closing price of $1.35.
Analyst Price Targets (3 )
Broker Rating
Reneo Pharmaceuticals, Inc. currently has an average brokerage recommendation (ABR) of 3.25 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 3.25 a month ago based on four recommendations.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 0 | 0 | 0 | 0 | 0 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 3 | 3 | 3 | 3 | 3 |
Sell | 1 | 1 | 1 | 1 | 1 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 3.25 | 3.25 | 3.25 | 3.25 | 3.25 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/2/2024 | H.C. Wainwright & Co. | Mitchell S Kapoor | Hold | Hold |
12/14/2023 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Hold |
12/14/2023 | LadenburgThalmann | Matthew L Kaplan | Strong Buy | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 3.25 |
ABR (Last week) | 3.25 |
# of Recs in ABR | 4 |
Average Target Price | $1.90 |
LT Growth Rate | 38.60% |
Industry | Medical - Drugs |
Industry Rank by ABR | 98 of 253 |
Current Quarter EPS Est: | -0.17 |